公开(公告)号：EP2900664B1

公开(公告)日：2017-12-13

申请号：EP13841041.0

申请日：2013-09-27

申请人： Sunshine Lake Pharma Co., Ltd.

发明人： ZHANG, Yingjun ,  REN, Qingyun ,  LIU, Xinchang ,  WANG, Chaolei ,  WANG, Tianming ,  GOLDMANN, Siegfried

IPC分类号： C07D417/04 ,  A61K31/506 ,  A61P31/12

CPC分类号： C07D417/04

摘要： The present invention relates to crystalline forms of dihydropyrimidine derivatives, and pharmaceutical compositions comprising the crystalline forms disclosed herein, which may be used for preventing, managing, treating or lessening the severity of a viral disease in a patient, especially hepatitis B infection or a disease caused by hepatitis B infection.

公开(公告)号：EP2900664A1

公开(公告)日：2015-08-05

申请号：EP13841041.0

申请日：2013-09-27

申请人： Sunshine Lake Pharma Co., Ltd.

发明人： ZHANG, Yingjun ,  REN, Qingyun ,  LIU, Xinchang ,  WANG, Chaolei ,  WANG, Tianming ,  GOLDMANN, Siegfried

IPC分类号： C07D417/04 ,  A61K31/506 ,  A61P31/12

CPC分类号： C07D417/04

摘要： The present invention relates to crystalline forms of dihydropyrimidine derivatives, and pharmaceutical compositions comprising the crystalline forms disclosed herein, which may be used for preventing, managing, treating or lessening the severity of a viral disease in a patient, especially hepatitis B infection or a disease caused by hepatitis B infection.

公开(公告)号：EP2760859A1

公开(公告)日：2014-08-06

申请号：EP12836570.7

申请日：2012-09-27

申请人： Sunshine Lake Pharma Co., Ltd ,  Ruyuan Hec Pharm Co., Ltd.

发明人： LEI, Xin ,  PENG, Jinan ,  WANG, Tianming ,  LV, Zhiqing ,  LI, Wan

IPC分类号： C07D413/10 ,  A61K31/4245 ,  A61P9/12

CPC分类号： C07D413/10

摘要： The present invention relates to the field of pharmaceutical chemistry. Disclosed herein is a crystalline form of azilsartan, which is substantially pure. The crystalline form is crystalline form A, form B, form C, form D, form E, form F, form G, form H, form I, form J or form K. The substantially pure crystalline forms of azilsartan of the invention generally have good properties such as high solubility, high bioavailability, good stability, long shelf life and good antistatic property. The crystalline forms of azilsartan generally exhibit an excellent performance in reducing clinical systolic blood pressure (SBP) and average 24-hour SBP. Disclosed herein are methods of preparing the substantially pure crystalline forms of azilsartan, pharmaceutical compositions comprising the crystalline forms, and preparation methods and uses thereof.